Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719721 | 0.81 | PDE10A (0.41) | PDE10ANPSR1MEN1KMT2AGAA | |
| SCHEMBL1609979 | 0.78 | PDE4B (0.42) | PDE10AALDH1A1SMN1; SMN2 | |
| SCHEMBL1610385 | 0.78 | PDE10A (0.40) | PDE10AMEN1KMT2A | |
| SCHEMBL1610432 | 0.78 | TSHR (0.40) | PDE10AMEN1KMT2AGAATSHR | |
| SCHEMBL1610224 | 0.77 | SLC6A3 (0.40) | PDE10AMEN1KMT2ATSHRMAPK1 | |
| SCHEMBL1609421 | 0.77 | PDE10A (0.43) | PDE10ANPSR1MEN1KMT2AGAA | |
| SCHEMBL1609728 | 0.77 | PDE10A (0.42) | PDE10AMEN1KMT2AGAACNR2 | |
| SCHEMBL1609605 | 0.77 | PDE10A (0.44) | PDE10AKMT2AGAAALDH1A1 | |
| SCHEMBL1609653 | 0.77 | PDE10A (0.41) | PDE10AMEN1KMT2ATSHRMAPK1 | |
| SCHEMBL1610294 | 0.76 | PDE10A (0.41) | PDE10AMEN1KMT2AGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009081112-A2 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | DDT, PNPO, CBR3 | PDE10A 1704/4885NPSR1 2070/4885MEN1 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.